We recently performed prognostic analysis including 4 subtypes (Luminal A, Luminal B, HER2, and Triple negative) in primary BC patients, and proved that Ki-67 has a great potential as a prognostic biomarker [24]. This evidence concerns the gene ERBB2 and breast cancer.